Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

Introduction: Checkpoint inhibitors, including the CTLA-4 blocking antibody ipilimumab, have become the new standard therapy for many metastatic cancers. Development of anti-drug antibodies (ADAs) after treatment with other biopharmaceuticals has been thoroughly described, but the induction of ADAs...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncoimmunology
Autori principali: Kverneland, Anders H., Enevold, Christian, Donia, Marco, Bastholt, Lars, Svane, Inge Marie, Nielsen, Claus H.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2018
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5927482/
https://ncbi.nlm.nih.gov/pubmed/29721387
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1424674
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi